Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's monthly FluidCrystal® semaglutide formulation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback